Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Neuroscience ; 273: 65-78, 2014 Jul 25.
Article in English | MEDLINE | ID: mdl-24836854

ABSTRACT

Aspirin-triggered Lipoxin A4 (ATL), as a Lipoxin A4 (LXA4) epimer, is endogenously produced by aspirin-acetylated cycloxygenase-2 (COX-2) and plays a vital role in endogenous anti-inflammation via the LXA4 receptor (ALX). Recent investigations have indicated that spinal neuroinflammation and the activation of the Janus Kinase 2 (JAK2)/Signal Transducers and Transcription Activators 3 (STAT3) signaling pathway are involved in neuropathic pain states. However, the effect of ATL on neuroinflammation and JAK2/STAT3 signaling in chronic constriction injury (CCI)-induced neuropathic pain in rats has not been well-studied. The present study demonstrated the anti-inflammatory and analgesic effect of ATL on neuropathic pain and assessed the role of spinal JAK2/STAT3 signaling on the effect of ATL. Intrathecal administration of ATL significantly attenuated mechanical allodynia via spinal ALX and inhibited the upregulation of pro-inflammatory cytokines (IL-1ß, IL-6, and TNF-α) on day 7 of CCI surgery. In addition, ATL markedly suppressed the upregulation of p-STAT3 induced by the neuropathic pain. Blockade of JAK2-STAT3 signaling with intrathecal administration of the JAK2 inhibitor AG490 or the STAT3 inhibitor S3I-201 clearly reduced mechanical allodynia and the upregulation of pro-inflammatory cytokines in CCI rats. Interestingly, inhibition of JAK2/STAT3 signaling via ATL or the specific signaling inhibitor (AG49, S3I-201) further promoted the increased expression of suppressor of cytokine signaling 3 (SOCS3) mRNA in the spinal cord induced by CCI surgery. Taken together, our results suggested that the analgesic effect of ATL was mediated by inhibiting spinal JAK2/STAT3 signaling and hence the spinal neuroinflammation in CCI rats.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Hyperalgesia/drug therapy , Lipoxins/administration & dosage , Neuralgia/drug therapy , Spinal Cord/drug effects , Animals , Aspirin/pharmacology , Astrocytes/drug effects , Astrocytes/physiology , Constriction, Pathologic , Disease Models, Animal , Hyperalgesia/physiopathology , Interleukin-1beta/metabolism , Interleukin-6/metabolism , Janus Kinase 2/antagonists & inhibitors , Janus Kinase 2/metabolism , Male , Neuralgia/physiopathology , Neuroimmunomodulation/drug effects , Neuroimmunomodulation/physiology , RNA, Messenger/metabolism , Rats, Sprague-Dawley , STAT3 Transcription Factor/antagonists & inhibitors , STAT3 Transcription Factor/metabolism , Sciatic Nerve/injuries , Signal Transduction/drug effects , Signal Transduction/physiology , Spinal Cord/physiopathology , Suppressor of Cytokine Signaling 3 Protein , Suppressor of Cytokine Signaling Proteins/metabolism , Touch , Tumor Necrosis Factor-alpha/metabolism
2.
Neuroscience ; 254: 230-40, 2013 Dec 19.
Article in English | MEDLINE | ID: mdl-24076348

ABSTRACT

Neuroinflammation plays an important role in nerve-injury-induced neuropathic pain, but the explicit molecular mechanisms of neuroinflammation in neuropathic pain remain unclear. As one of the most critical inflammatory cytokines, interleukin-1ß (IL-1ß) has been regarded as broadly involved in the pathology of neuropathic pain. The inflammasome caspase-1 platform is one primary mechanism responsible for the maturation of IL-1ß. Lipoxins, a type of endogenous anti-inflammatory lipid, have proved to be effective in relieving neuropathic pain behaviors. The present study was designed to examine whether the inflammasome caspase-1 IL-1ß platform is involved in chronic constriction injury (CCI)-induced neuropathic pain and in lipoxin-induced analgesia. After rats were subjected to the CCI surgery, mature IL-1ß was significantly increased in the ipsilateral spinal cord, and the inflammasome platform consisting of NALP1 (NAcht leucine-rich-repeat protein 1), caspase-1 and ASC (apoptosis-associated speck-like protein containing a caspase-activating recruitment domain) was also activated in spinal astrocytes and neurons, especially at the superficial laminae of the spinal dorsal horn; The aspirin-triggered-15-epi-lipoxin A4 (ATL), which shares the potent actions of the endogenous lipoxins, was administered to the CCI rats. Repeated intrathecal injection with ATL markedly attenuated the CCI-induced thermal hyperalgesia and significantly inhibited NALP1 inflammasome activation, caspase-1 cleavage, and IL-1ß maturation. These results suggested that spinal NALP1 inflammasome was involved in the CCI-induced neuropathic pain and that the analgesic effect of ATL was associated with suppressing NALP1 inflammasome activation.


Subject(s)
Aspirin/administration & dosage , Inflammasomes/biosynthesis , Lipoxins/administration & dosage , Nerve Tissue Proteins/biosynthesis , Neuralgia/metabolism , Spinal Cord/metabolism , Analgesia/methods , Animals , Chronic Disease , Drug Therapy, Combination , Injections, Spinal , Male , Neuralgia/drug therapy , Rats , Rats, Sprague-Dawley , Spinal Cord/drug effects
3.
Neuroscience ; 253: 172-82, 2013 Dec 03.
Article in English | MEDLINE | ID: mdl-23988433

ABSTRACT

Cancer pain, particularly bone cancer pain, affects the quality of life of cancer patients, and current treatments are limited. Interleukin (IL)-33, a new member of the IL-1 super family, has been reported to be involved in the modulation of inflammatory pain. However, studies focused on its role in the modulation of cancer pain have been rare. The present study was designed to investigate whether spinal IL-33/ST2 signaling was involved in bone cancer-induced pain in mice. Bone cancer was induced via intra-femoral inoculation of 4T1 mammary carcinoma cells. The mice inoculated with carcinoma cells showed mechanical allodynia, heat hyperalgesia and a reduction in limb use, whereas phosphate-buffered saline or heat-killed cells-injected mice showed no significant difference compared to non-treated mice. The pain hypersensitive behaviors worsened over time and with bone destruction. Both the mRNA and the protein levels of IL-33 and relative cytokines (IL-1ß, IL-6, TNF-a) were significantly increased in the spinal cord after the inoculation of carcinoma cells. Intrathecal administration of ST2 antibody to block IL-33/ST2 signaling alleviated pain behaviors in a dose-dependent manner in bone cancer pain mice compared with vehicle-injected mice. Moreover, the ST2(-/-) mice showed a significant amelioration of limb use and heat hyperalgesia compared to wild-type mice. Meanwhile, concentrations of spinal IL-1ß, IL-6 and TNF-a in the cancer-bearing ST2(-/-) mice had no significant changes. These data further suggested that IL-33/ST2 signaling played a vital role in cancer pain. Our results provided evidence that IL-33 and its receptor ST2 may be a potential therapeutic target for the treatment of pain in bone cancer patients.


Subject(s)
Bone Neoplasms/complications , Interleukins/metabolism , Pain/etiology , Pain/pathology , Receptors, Interleukin/metabolism , Spinal Cord/metabolism , Animals , Bone and Bones/diagnostic imaging , Bone and Bones/pathology , Carcinoma/complications , Cell Line, Tumor/pathology , Disease Models, Animal , Female , Hyperalgesia/metabolism , Hyperalgesia/pathology , Hyperalgesia/physiopathology , Immunoglobulin G/therapeutic use , Interleukin-1 Receptor-Like 1 Protein , Interleukin-33 , Interleukins/immunology , Locomotion/physiology , Mice , Mice, Inbred BALB C , Mice, Knockout , Pain/drug therapy , Pain Measurement , Radiography , Receptors, Interleukin/deficiency , Receptors, Interleukin/genetics , Time Factors
4.
Neuroscience ; 241: 59-66, 2013 Jun 25.
Article in English | MEDLINE | ID: mdl-23523996

ABSTRACT

Interleukin-33 (IL-33), a member of the IL-1 family, has attracted growing interest since its discovery in 2003. IL-33 has been implicated in many diseases, including arthritis, asthma, allergies, and cardiovascular and infectious diseases. However, few studies have investigated its role in the transmission and modulation of pain. The present study was designed to explore the possible roles of IL-33 and its receptor, ST2, in formalin-induced inflammatory pain in mice. We found that both subcutaneous (s.c., 300 ng) and intrathecal injection (i.t., 3 ng) of recombinant IL-33 (rIL-33) increased paw lifting and licking time not only in normal mice but also in formalin models. Administration of ST2 antibody, which blocked the IL-33/ST2 signaling, alleviated the formalin-induced spontaneous pain behavior. Moreover, the ST2(-/-) mice showed significantly decreased pain behavior, as well as reduced ultrasonic vocalization induced by formalin, compared with the wild-type group. Additionally, ST2 antibody alleviated the potentiating effects of rIL-33 on pain behavior in the formalin mice, indicating that IL-33 plays a role in pain modulation through its ST2 receptor. These data suggest IL-33 and its ST2 receptor mediate formalin-induced inflammatory pain, and as a result this cytokine and its receptor may be new targets for the development of analgesics.


Subject(s)
Inflammation/metabolism , Interleukins/metabolism , Pain/metabolism , Receptors, Interleukin/metabolism , Animals , Behavior, Animal/drug effects , Formaldehyde/toxicity , Inflammation/chemically induced , Interleukin-1 Receptor-Like 1 Protein , Interleukin-33 , Irritants/toxicity , Mice , Mice, Inbred BALB C , Mice, Knockout , Pain/chemically induced , Signal Transduction/drug effects
5.
Neuroscience ; 217: 172-81, 2012 Aug 16.
Article in English | MEDLINE | ID: mdl-22564552

ABSTRACT

Cancer pain, especially cancer-induced bone pain, affects the quality of life of cancer patients, and current treatments for this pain are limited. The present study demonstrates that spinal extracellular signal-regulated kinase (ERK) activation in glial cells plays a crucial role in cancer-induced bone pain. From day 4 to day 21 after the intra-tibia inoculation with Walker 256 mammary gland carcinoma cells, significant mechanical allodynia was observed as indicated by the decrease of mechanical withdrawal thresholds in the von Frey hair test. Intra-tibia inoculation with carcinoma cells induced a vast and persistent (>21 D) activation of ERK in the bilateral L2-L3 and L4-L5 spinal dorsal horn. The increased pERK1/2-immunoreactivity was observed in both Iba-1-expressing microglia and GFAP-expressing astrocytes but not in NeuN-expressing neurons. A single intrathecal injection of the selective MEK (ERK kinase) inhibitors PD98059 (10 µg) on day 12 and U0126 (1.25 and 3 µg) on day 14, attenuated the bilateral mechanical allodynia in the von Frey hair test. Altogether, our results suggest that ERK activation in spinal microglia and astrocytes is correlated with the onset of allodynia and is important for allodynia maintenance in the cancer pain model. This study indicated that inhibition of the ERK pathway may provide a new therapy for cancer-induced bone pain.


Subject(s)
Astrocytes/metabolism , Bone Neoplasms/metabolism , Carcinoma/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Microglia/metabolism , Pain/metabolism , Animals , Behavior, Animal , Bone Neoplasms/complications , Carcinoma/complications , Female , Hyperalgesia/etiology , Hyperalgesia/metabolism , Neoplasm Transplantation , Neurons/metabolism , Pain/etiology , Pain Measurement , Phosphorylation , Rats , Rats, Wistar
6.
Pharmacogenomics J ; 8(6): 375-83, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18195730

ABSTRACT

Adult hippocampal neurogenesis has been demonstrated in several species and is regulated by both environmental and pharmacological stimuli. Repeated exposure to stress is known to induce the reduction of neurogenesis in the dentate gyrus (DG) of hippocampus. The present study aimed at determining whether the clinically effective antidepressant clomipramine may influence hippocampal proliferation and neurogenesis in adult rats subjected to the chronic unpredictable stress (CUS) procedure, a model of depression with predictive validity. Repeated administration of clomipramine (5 mg kg(-1), intraperitoneal) for 3 weeks, starting 2 weeks after the beginning of the stress procedure, significantly reversed the reduction of behavior measured by open-field test and forced swimming test. Moreover, rats subjected to stress exhibited a 49.9% reduction of cell proliferation at the end of a 5-week stress period, an effect which was suppressed by clomipramine treatment. These results demonstrated that exposure to CUS, which results in a state of behavioral depression, decreases hippocampal cell proliferation and that these effects can be counteracted by chronic clomipramine treatment.


Subject(s)
Cell Proliferation/drug effects , Clomipramine/administration & dosage , Hippocampus/drug effects , Selective Serotonin Reuptake Inhibitors/administration & dosage , Stress, Physiological , Animals , Behavior, Animal , Chronic Disease , Clomipramine/pharmacology , Hippocampus/cytology , Male , Rats , Rats, Sprague-Dawley , Selective Serotonin Reuptake Inhibitors/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...